To observe the clinical effect of neoadjuvant chemotherapy combined with surgery in the treatment of local advanced gastric-esophageal junction (EGJ) adenocarcinoma.

Eighty-one patients with locally advanced EGJ adenocarcinoma admitted to the Department of Oncology in Yangzhong City People's Hospital from March 2012 to January 2014 were divided into treatment group and control group according to the random number table. Treatment group of 41 patients underwent capecitabine and oxaliplatin combined with or without paclitaxel chemotherapy for 2 to 4 cycles, and then surgery and postoperative adjuvant chemotherapy for 2 to 4 cycles. Forty patients of the control group were treated surgically with capecitabine and oxaliplatin in combination with or without paclitaxel for 4 to 6 cycles. Comparative analysis was carried out of postoperative pathological staging, surgical complications, adverse drug reactions and disease-free survival of the two groups of patients.

There were no fatal complications in the treatment group, while the incidence rate was 4.9% (2/41) in the treatment group and 22.5% (9/40) in the control group. The incidence of complications was statistically significant (χ²=5.357, P=0.021).

Neoadjuvant chemotherapy regimens in the treatment of locally advanced gastric-esophageal junctions is safe and accurate. It can reduce staging, delay recurrence, improve disease-free survival and benefit patients. It is worthy to be popularized.